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Background
Hypovolemic status (e.g. sepsis, trauma) is common
situation in emergency department. The patients should
be given a lot of fluid to prevent circulatory collapse with
following early goal directed therapy or massive transfu-
sion protocol in ED. ICU physician usually give some
diuretics, as the patients are in hypervolemic status.
Tolvaptan is an oral, non-peptide, selective antagonist of
vasopressin V2-receptor whose action on the distal
nephron causes loss of electrolyte-free water. We evalu-
ate the side effects of tolvaptan for overhydrate status
after fluid resuscitation in the critical care field.
Methods
The indications of administration for tolvaptan are over-
hydration and normal range of serum sodium and renal
functions. 7.5mg or 15mg tolvaptan tablets were given
once a day for a couple of day in refilling phase after fluid
resuscitation. Electrolyte and blood gases were followed al
least three times a day in all patients. The enrolled patients
were divided into the normal-dose group and low-dose
group. Any complications, especially serum sodium level,
renal function and neurological outcome were compared.
Results
A total of 62 patients were enrolled in this study. There
was no significant difference in the both groups (the low-
dose group; n = 29, average 8.6mg/day, the normal-dose
group; n = 33, average 12.9mg/day). Though hyperso-
dium was tend to occur in normal-dose group, any mor-
tal complications were not seen in the both groups.
Conclusions
Administration for tolvaptan is alternative method to
improve over-hydration without serious adverse events.
But strict collections of blood sample are recommended
to prevent any complications such as central pontine
myelinolysis.
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